ADIENNE SA
PharmaADIENNE SA is a pharmaceutical company focused on Oncology. Key products include TEPADINA AND SODIUM CHLORIDE.
ADIENNE SA's Key Drugs
ADIENNE SA's core commercial portfolio centers on TEPADINA AND SODIUM CHLORIDE, TEPADINA, spanning Oncology — its most strategically important drugs approved in the last 15 years.
ADIENNE SA's Recent FDA Approvals
New NDA/BLA approvals for ADIENNE SA over the last two years — novel drugs only, excluding generics and label supplements.
ADIENNE SA's Therapeutic Areas
ADIENNE SA's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ADIENNE SA's Top Competitors
ADIENNE SA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ADIENNE SA Pipeline Snapshot
Active clinical trials for ADIENNE SA across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TEPADINA AND SODIUM CHLORIDE leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (0)
Company Info
- First Approval
- 2017-01-26
- Latest
- 2026-01-15
- Applications
- 1